Harout Semerjian - Net Worth and Insider Trading

Harout Semerjian Net Worth

The estimated net worth of Harout Semerjian is at least $35,250 dollars as of 2023-10-03. Harout Semerjian is the CEO of GlycoMimetics Inc and owns about 25,000 shares of GlycoMimetics Inc (GLYC) stock worth over $35,250. Details can be seen in Harout Semerjian's Latest Holdings Summary section.

Transaction Summary of Harout Semerjian


Harout Semerjian Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Harout Semerjian owns 2 companies in total, including Immunomedics Inc (IMMU) , and GlycoMimetics Inc (GLYC) .

Click here to see the complete history of Harout Semerjian’s form 4 insider trades.

Insider Ownership Summary of Harout Semerjian

Ticker Comapny Transaction Date Type of Owner
IMMU Immunomedics Inc 2020-04-16 director & President and CEO
GLYC GlycoMimetics Inc 2021-08-06 director & Chief Executive Officer

Harout Semerjian Latest Holdings Summary

Harout Semerjian currently owns a total of 1 stock. Harout Semerjian owns 25,000 shares of GlycoMimetics Inc (GLYC) as of November 11, 2022, with a value of $35,250.

Latest Holdings of Harout Semerjian

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GLYC GlycoMimetics Inc 2022-11-11 25,000 1.41 35,250

Holding Weightings of Harout Semerjian

Harout Semerjian Form 4 Trading Tracker

According to the SEC Form 4 filings, Harout Semerjian has made a total of 1 transactions in GlycoMimetics Inc (GLYC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in GlycoMimetics Inc is the acquisition of 25,000 shares on November 11, 2022, which cost Harout Semerjian around $32,250.

Insider Trading History of Harout Semerjian

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Harout Semerjian Trading Performance

GuruFocus tracks the stock performance after each of Harout Semerjian's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Harout Semerjian is 180.65%. GuruFocus also compares Harout Semerjian's trading performance to market benchmark return within the same time period. The performance of stocks bought by Harout Semerjian within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Harout Semerjian's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Harout Semerjian

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 66.94 180.65 40.32
Relative Return to S&P 500(%) 68.41 178.21 36.87

Harout Semerjian Ownership Network

Ownership Network List of Harout Semerjian

No Data

Ownership Network Relation of Harout Semerjian

Harout Semerjian Owned Company Details

What does Immunomedics Inc do?

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Who are the key executives at Immunomedics Inc?

Harout Semerjian is the director & President and CEO of Immunomedics Inc. Other key executives at Immunomedics Inc include director & 10 percent owner & other: See Remarks Venbio Select Advisor Llc , director & 10 percent owner & other: See Remarks Behzad Aghazadeh , and Chief Human Resources Officer Kurt J. Andrews .

Immunomedics Inc (IMMU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immunomedics Inc (IMMU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunomedics Inc (IMMU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immunomedics Inc (IMMU)'s detailed insider trading history can be found in Insider Trading Tracker table.


Immunomedics Inc Insider Transactions

No Available Data

Harout Semerjian Mailing Address

Above is the net worth, insider trading, and ownership report for Harout Semerjian. You might contact Harout Semerjian via mailing address: 300 The American Road, C/o Immunomedics, Inc., Morris Plains Nj 07950.

Discussions on Harout Semerjian

No discussions yet.